PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3506.1000-002		PLICATION NO. 1757,364	
STATEMENT STATEMENT IN AN APPLICATION	FIRST NAMED INVENTOR Steven B. Landau		FILING DATE January 13,	2004
OCT 0 4 2006 September 29, 2006 (Use several sheets if necessary)	EXAMINER Yong Soo Chong	CONF. 3343	IRMATION NO.	GROUP 1617

	U.S. PATENT DOCUMENTS				
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	
Yc	AD6	US 2005/0239792	10-27-2005	Cavalla et al.	
	AE6	US 6,008,227	12-28-1999	Davies et al.	

FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANS	LATION NO
	AQ3	EP 0 150 469	06-15-1988	Mitsubishi		
	AL4	CA 2431074	6-27-2002	Merck Patent GMBH		
	AM4	DE 100 63 223	6-20-2002	Merck Patent GMBH		

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
AWS	Crowell, M. D., "The Role of Serotonin in the Pathophysiology of Irritable Bowel Syndrome," Am. J. Man. Care, 7: S252-S260 (2001).			

DATE CONSIDERED EXAMINER 7/16/07

@PFDesktop\::ODMAYHODMAN:TISKO5;iManage;653511;1

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3506.1000-002	1	PLICATION NO. /757,364		
P INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION			FILING DATE January 13,	G DATE lary 13, 2004	
May 24, 2006 May 24, 2006 May 24, 2006	EXAMINER Yong Soo Chong	CONF 3343	IRMATION NO.	GROUP 1617	

		U.S. P.	ATENT DOCUMENTS	
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
Yc	AF5	6,475,078 B2	11-05-2002	Jerussi et al.
	AG5	2004/0254168 A1	12-16-2004	Landau
	AH5	2004/0254169 A1	12-16-2004	Landau ·
	Al5	2004/0254170 A1	12-16-2004	Landau
	AJ5	2004/0259862 A1	12-23-2004	Landau
	AK5	2005/0032780 A1	02-10-2005	Landau
	AA6	2004/0254171 A1	12-16-2004	Landau <i>et al</i> .
	AB6	2004/0254172 A1	12-16-2004	Landau et al.
	AC6	2004/0147510 A1	07-29-2004	Landau

	FOREIGN PATENT DOCUMENTS					
			DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO
	A	Р3	WO 2004/062624 A3	07-29-2004	Dynogen Pharmaceuticals, Inc.	

L		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AS	Steadman, C.J., et al., "Selective 5-Hydroxytryptamine Type 3 Receptor Antagonism With Ondansetron as Treatment for Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Study," Mayo Clinic Proc., 67(8): 732-738 (1992).			
	AT	"Dynogen Pharmaceuticals, Inc. Enters Into Agreement With Mitsubishi Pharma For Irritable Bowel Syndrome Compound," Dynogen Pharmaceuticals, Inc. Press Release, pp. 1-2 [online], (December 22, 2003). Retrieved from the Internet <url: <a="" href="www.dynogen.com">www.dynogen.com.</url:>			
	AU	Database IMSDRUGNEWS, R&D Focus Drug News, "DDP 225 Dynogen, Mitsubishi Pharma Licensing Agreement," [online], January 12, 2004. Retrieved from: STN Database, Accession No. 2004:188.			
	AV	Database CIN 2004-01-05, "Life Sciences in Brief," [online], January 5, 2004 (retrieved online January 31, 2006). Retrieved from: STN Database, Accession No. 33(3):1518T			

EXAMINER Jong Kong	DATE CONSIDERED 7/16/07	
@PFDesktop\::ODMA/HDDMA/HB\$R05;iManage;625767;1		

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3506.1000-002	APPLICATION NO. 10/757,364	Sheet 1 of
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	FIRST NAMED INVENTOR Steven B. Landau	FILING DATE January 13,	2004
April 8, 2005 APR 1 5 2005 (Use several sheets if necessal	I EXAMINER (CONFIRMATION NO. 3343	GROUP 1653
PADEWIT			

U.S. PATENT DOCUMENTS				
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
YL	AD5	2002/0039599 A1	04-04-2002	Lin et al.
1	AE5	6,476,078 B2	11-05-2002	Jerussi et al.
			·	
		•		

EXAMINER O	DATE CONSIDERED
Jay Chony	7/14/07
	The in i
@PFDesktop\::ODMA/MYODMA/HBSROS/iManage;542283;1	

heet	7	Ωf	•

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3506.1000-002		LICATION NO. 757,364	
IN AN APPLICATION	FRST NAMED INVENTOR Steven B. Landau		FILING DATE January 13,	2004
April 8, 2005	EXAMINER		RMATION NO.	GROUP
(Use several sheets if necessary)	-18	3343		1653

	TRADE				
	,	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
*K	AR5	"How to Avoid a Health Insurance Claim Denial- and What to do When You Can't," [Retrieved on 03-15-2005]. Retrieved from the Internet <url:http: claimdenial.html="" health="" info.insure.com=""></url:http:>			
		•			
•					
	,				
		ł			
7					
		•			

EXAMINER Jay Chon	DATE CONSIDERED 7/4/07
@PFDesktop\:ODMAYHODMA/HB\$\t05;iManage;542283;1	

, ')				Sheet 1 of
PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3506.1000-002		LICATION NO. 757,364	
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Steven B. Landau	. I	FILING DATE January 13,	2004
December 6, 2004 (So several sheets if necessary)	EXAMINER	CONFI 3343	RMATION NO.	GROUP 1653
8410/				· · · · · · · · · · · · · · · · · · ·

	FOREIGN PATENT DOCUMENTS							
	,	DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO			
.40	ΑLJ	WO 2004/058353 A3	07-15-2004	Amedis Pharmaceuticals, LTD.				

EXAMINEB DATE CONSIDERED 7/66/67

@PFDcsktopv:ODMA/MHODMA/HBSB05;iManage;518148;1

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3506.1000-002 FIRST NAMED INVENTOR Steven B. Landau APPLICATION NO. 10/757,364 FILING DATE January 13, 2				
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION			2004		
September 27, 2004 (Use several sheets if necessary)	EXAMINER	CONF 3343	RMATION NO.	GROUP	

		U.S. PA	TENT DOCUMENTS	
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
YC	AC5	US 2004/0048874 A1	03-11-2004	Bardsley et al.
		OIPE		
		SEP 2 8 2004 34		
		SE S S SOM IN		
		·		
				·

EXAMINER	DATE CONSIDERED / /
I have land	7/60/07
7.70.07	1,000
COTO - I COOKA DATION A REPORT AND ADDRESS AS A SECOND AS A	

PTO-1449 REPRODUCED ATTORNEY DOCKET NO. APPLICATION NO. 3506.1000-002 10/757,364 TION DISCLOSURE CITATION LAN APPLICATION FIRST NAMED INVENTOR FILING DATE Steven B. Landau January 13, 2004 March 19, 2004 EXAMINER CONFIRMATION NO. GROUP veral sheets if necessary) Unknown Unknown Unknown

	U.S. PATENT DOCUMENTS						
EXAM- INER INI- INI- TIAL DOCUMENT NUMBER Number-Kind Code (if known) SSUE DATE / PUBLICATION DATE MM-DD-YYYY NAME OF PATENTEE OR APPL OF CITED DOCUMENT							
40	AB5	2003/0158221 A1	08-21-2003	Zhang et al.			

	· · · · · · · · · · · · · · · · · · ·	F	OREIGN PATENT D	OCUMENTS		
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSI YES	LATION NO
Ye	AQ2	WO 03/061657 A1	07-31-2003	Aryx Therapeutics		

DATE CONSIDERED 7/16/7

@PFDesktop\::ODMAMHODMA/HBSR09;iManage;459692;1

PTO-1449 REPRODUCED P INFORMATION DISCLOSURE CITATION IN AN APPLICATION			APPLICATION NO. 10/757,364	
	FIRST NAMED INVENTOR Steven B. Landau		FILING DATE January 13, 2004	
February 11, 2004 (Use several sheets if necessary)	examiner Unknown		RMATION NO.	GROUP Unknown

	U.S. PATENT DOCUMENTS				
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	
Ye	AA	4,695,568	09-22-1987	Ninomiya et al.	
	AÐ	4,939,136	07-03-1990	Haeck et al.	
	AC	5,225,407	07-06-1993	Oakley et al.	
	AD	5,352,685	10-04-1994	Maruyama et al.	
	AE	5,434,174	07-18-1995	Gidda et al.	
	AF	5,438,068	08-01-1995	Eeckhout et al.	
	AG	5,470,868	11-28-1995	Young	
	AH	5,576,317	11-19-1996	Gonsalves	
	AK	5,663,343	09-02-1997	van der Meij et al.	
	ΑJ	5,945,415	08-31-1999	Kato et al.	
	AK	5,962,494	10-05-1999	Young	
	AA2	5,977,175	11-02-1999	Lin-	
	AB2	5,985,866	11-16-1999	Müller et al.	
	AG2	5,990,159	11-23-1999	Meulemans et al.	
	AD2	6,054,461	04-25-2000	Fairbanks et al.	
	AE2	6,117,879	09-12-2000	Fairbanks et al.	
	AF2	6,156,771	12-05-2000	Rubin et al.	
	AG2	6,235,745 B1	05-22-2001	Megens	
	AH2	6,284,770 B1	09-04-2001	Mangel et al.	
	Al2	6,300,336 B1	10-09-2001	Eeckhout et al.	
	AJ2	6,355,647 B1	09-12-2000	Steiner et al.	
	AK2	6,384,042 B2	05-07-2002	Färber et al.	
	AA3	6,429,209 B2	08-06-2002	Mangel et al.	
	AB3	6,440,453 B1	08-27-2002	Fischer et. al.	
	AC3	6,441,038 B1	08-27-2002	Loder et al.	
	AD3	6,458,795 B1	10-01-2002	Bergeron, Jr.	

EXAMINER —	DATE CONSIDERED
May May	7/16/07
@PEDeskionl::ODM #ALKODM & /HRSDOK: Manage: 450605:1	<u> </u>

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3506.1000-002				
February 11, 2004 See several sheets if necessary)			FILING DATE January 13,	2004	
	EXAMINER Unknown		IRMATION NO.	GROUP Unknown	

	<u> </u>		S. PATENT DOCUMENTS	
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
4	AE3	6,465,458 B1	10-15-2002	Wong et al.
1	AF3	6,566,369 B2	05-20-2003	Cautreels et al.
	AG3	6,588,708 B1	05-06-2003	Lin
F. W.	АН3	2001/0020025 A1	09-06-2001	Megens
	AI3	2001/0044450 A1	11-22-2001	Mangel et al.
	AJ3	2001/0056110 A1	12-27-2001	Faerber et al.
	AK3	2002/0002197 A1	01-03-2002	Mueller et al.
	AA4	2002/0040033 A1	04-04-2002	Cautreels et al.
	AB4	2002/0086880 A1	07-04-2002	Rubin et al.
	AC4	2002/0086881 A1	07-04-2002	Rubin et al.
	AD4	2002/0107244 A1	08-08-2002	Howard, Jr.
	AE4	2003/0125349 A1	07-03-2003	Cautreels et al.
	AF4	2003/0203055 A1	10-30-2003	Rao et al.
	AG4	6,593,336 B2	07-15-2003	Mangel et al.
	AH4	2003/0036549 A1	02-20-2003	Mangel et al.
	Al4	6,211,171 B1	04-03-2001	Sawynok et al.
	AJ4	5,530,008	06-25-1996	Azcona et al.
	AK4	5,977,127	11-02-1999	Bonnacker et al.
	AA5	4,845,092	07-04-1989	Sanger et al.

EXAMINER Ung Chay	DATE CONSIDERED 7/16/07
OPED-sheet ODA (MINGDA A MB 90 ds Manager 450605)	

PTO-1449 F	REPRODUCED
------------	------------

February 11, 2004

se several sheets if necessary)

ATTORNEY DOCKET NO. 3506.1000-002

APPLICATION NO. 10/757,364

Unknown

FIRST NAMED INVENTOR Steven B. Landau

EXAMINER

Unknown

FILING DATE

January 13, 2004 CONFIRMATION NO.

GROUP Unknown

	10.1135		FOREIGN PATENT D	OCUMENTS			
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT		TRANSLATION YES NO	
Y	AL	WO 01/26623 A3	04-19-2001	Laxdale Limited			
-	AM	EP 1 230 921 A1	08-14-2002	Pfizer Products, Inc.			
	AN	WO 02/083926 A3	10-24-2002	Cedars-Sinai Medical Center			
	AO	WO 00/48597	08-24-2000	Novartis AG			
	AP	WO 00/48581 A3	08-24-2000	Novartis AG			
	AQ	WO 00/51583	09-08-2000	Sepracor, Inc.			
	AL2	WO 2004/004734 A1	01-15-2004	Arachnova Therapeutics Ltd.			
	AM2	WO 00/51584	09-08-2000	Sepracor, Inc.			
	AN2	WO 02/07713 A2	01-31-2002	Solvay Pharmaceuticals GMBH		X	
	AO2	EP 0 297 651 B1	01-04-1989	Duphar International Research B.V			
	AP2	WO 02/094249 A1	11-28-2002	Arachnova Therapeutics Ltd.		•	
	AQ2	WO 03/077897 A1	09-25-2003	Cypress Bioscience, Inc.			
	AL3	WO 94/01095 A3	01-20-1994	Smith-Kline Beecham PLC			
	AM3	WO98/50037	11-12-1998	Mitsubishi Chemical Corporation		Х	
•				·			
•					· · · · · · · · · · · · · · · · · · ·		
		, (A = 0, A = 0,			·····		
		·	<u> </u>				

EXAMINER OF	y Chong
@PFDesktop\::ODMAN	AODMA/HBSR05;iManage;450605;1

DATE CONSIDERED

7/16/07 1

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3506.1000-002 APPLICATION NO. 10/757,364			
P PORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Steven B. Landau FILING DATE January 13, 2004		2004	
February 11, 2004 See several sheets if necessary)	examiner Unknown	CONFIR	MATION NO.	group Unknown

XQ		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
yı	AR	Depoortere, I., et al., "Dose-Dependent Effects of Recombinant Human Interleukin-11 on Contractile Properties in Rabbit 2,4,6-Trinitrobenzene Sulfonic Acid Colitis ¹ ," J. Pharmacol. Exp. Ther., 294(3): 983-990 (2000).
	AS	Million, M., et al., "Susceptibility of Lewis and Fischer Rats to Stress-induced Worsening of TNB-colitis: Protective Role of Brain CRF," Amer. Phys. Soc., 276 (4 Pt 1): G1027-G1036 (1999).
	AT	Owens, M. J., et al., "Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and their Metabolites ¹ ," J. Pharmacol. Exp. Ther., 283(3): 1305-1322 (1997).
•	AU	Kozlowski, C.M., et al., "The 5-HT ₃ Receptor Antagonist Alosetron Inhibits the Colorectal Distention Induced Depressor Response and Spinal c-fos Expression in the Anaesthetised Rat," Gut, 46: 474-480 (2000).
	AV	Ito, C., et al., "Effect of GK-128 [2-[(2-Methylimidazol-1-yl)methyl]- benzo[f]thiochromen-1-one Monohydrochloride Hemihydrate], a Selective 5-Hydroxytryptamine, Receptor Antagonist, on Colonic Function in Rats," J. Pharmacol. Exp. Ther., 280(1): 67-72 (1997).
	AW	Eguchi, J., et al., "Pharmacological Profile of the Novel Antidepressant 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno-[2,3-d]pyrimidine Monohydrate Hydrochloride," Arzneimittelforschung, 47(12): 1337-1347 (1997).
	AX	Venkova, K., et al., "Peripheral Activity of a New NK ₁ Receptor Antagonist TAK-637 in the Gastrointestinal Tract," J. Pharmacol. Exp. Ther., 300(3): 1046-1052 (2002).
	AY	Yuan, S.Y., et al., "Investigation of the Role of 5-HT ₃ and 5-HT ₄ Receptors in Ascending and Descending Reflexes to the Circular Muscle of Guinea-pig Small Intestine," Br. J. Pharmacol., 112(4): 1095-1100 (1994).
	AZ	Jin, J.G., et al., "Propulsion in Guinea Pig Colon Induced by 5-Hydroxytryptamine (HT) Via 5-HT ₄ and 5-HT ₃ , Receptors ¹ ," J. Pharmacol. Exp. Ther., 288(1): 93-97 (1999).
	AR2	Greenbaum, D.S., et al., "Effects of Desipramine on Irritable Bowel Syndrome Compared with Atropine and Placebo," Digestive Diseases and Sciences, 32(3): 257-266 (1987).
	AS2	Center for Drug Evaluation and Research Application Number: 020623; Pharmacology Reviews; July 5, 1996.

EXAMINER Way Chay	DATE CONSIDERED 1/6/07	
@PFDesktop\::ODM/MHODMA/HBSR05;iManage;450605;1		

PTO-1449 REPRODUCED INCORMATION DISCLOSURE CITATION	ATTORNEY DOCKET NO. 3506.1000-002 APPLICATION NO. 10/757,364			
PECKMATION DISCLOSURE CITATION ON AN APPLICATION	FIRST NAMED INVENTOR Steven B. Landau		FILING DATE January 13, 2004	
(Use several sheets if necessary)	examiner Unknown		RMATION NO. 10WN	group Unknown

	OTHER DOCUMENTS (Including Author Title Data Partingst Pages Fig.)							
<u> </u>	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
Yc	AT2	Eguchi, J., et al., "The Anxiolytic-Like Effect of MCI-225, A Selective NA Reuptake Inhibitor with 5-HT, Receptor Antagonism," Pharm. Biochem. and Behavior, 68:677-683 (2001).						
	AU2	Schmulson, M.J., "Brain-Gut Interaction in Irritable Bowel Syndrome: New Findings of a Multicomponent Disease Model," <i>IMAJ</i> , 3:104-110 (2001).						
	AV2	Camilleri, M., "Serotonergic Modulation of Visceral Sensation: Lower Gut," Gut 51(1):81-86 (2002).						
	AW2	Camilleri, M., "Serotonergic Drugs: Emerging Therapies for Irritable Bowel Syndrome," In <i>Irritable Bowel Syndrome a Clinician's Guide</i> , M. Camilleri and R. C. Spiller, eds., Chapt. 19; pp 1-10 (2002).						
	AX2	Wood, J.D., et al. "Fundamentals of Neurogastroenterology," Gut 45(2):II6-II16 (1999).						
	AY2	Burns, M.J., "The Pharmacoloty and Toxicology of Reboxetine," Int. J. Med. Toxicol. 3(4):26 1-8 (2000).						
	AZ2	Thompson, W.G., et al., "Functional Bowel Disorders and Functional Abdominal Pain," Gut 45:II43-II47 (1999).						
	AR3	Sheikh, M. Y. and Wright, R.A., "Irritable Bowel Syndrome: Current Concepts and Future Prospects," <i>Hospital Physician</i> , pp. 31-38 (March 1999).						
	AS3	Schmulson, M.J., "Brain-Gut Interaction in Irritable Bowel Syndrome: New Findings of a Multicomponent Disease Model," <i>IMAJ</i> 3:104-110 (2001).						
	АТ3	Gebhart, G.F., "Pathobiology of Visceral Pain: Molecular Mechanisms and Therapeutic Implications IV. Visceral Afferent Contributions to the Pathobiology of Visceral Pain," Am. J. Physiol. Gastrointest. Liver Physiol. 278:G834-G838 (2000).						
	AU3	Mertz, H.R., "Irritable Bowel Syndrome," N. Engl. J. Med. 349:2136-2146 (2003).						
	AV3	Bymaster, F.P., et al. "Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters In Vitro and In Vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors," Neuropsychopharmacology, 25(6):871-880 (2001).						
	AW3	Béïque, J.C., et al., Affinities of Venlafaxine and Various Reuptake Inhibitors for the Serotonin and Norepinephrine Transporters," Eur. J. Pharmacol., 349(1):129-132 (1998).						

EXAMINER Jay Chay	DATE CONSIDERED 7/16/07
@PFDesktop\::ODMAMHODMA/HBSR05:iManage:450605:1	

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3506.1000-002	APPLICATION NO. 10/757,364		_
PINEORMATION DISCLOSURE CITATION C IN AN APPLICATION			FILING DATE January 13, 2004	
February 11, 2004 (See several sheets if necessary)	examiner Unknown		RMATION NO.	group Unknown

Company of the second of the s							
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
40	AX3	Wong, E.H.F., et al., "Reboxetine: A Pharmacologically Potent, Selective, and Specific Norepinephrine Reuptake Inhibitor," Biol. Psychiatry. 47(9): 818-829 (2000).					
	AY3	Sach, J.A., et al., "Irritable Bowel Syndrome," Curr. Treat. Options. Gastroenterol., 5(4): 267-278 (2002).					
	AZ3	Angel, I., et al. "Litoxetine: A Selective 5-HT Uptake Inhibitor with Concomitant 5-HT ₃ Receptor Antagonist and Antiemetic Properties," Eur. J. Pharmacol., 232(2-3):139-145 (1993).					
•	AR4	Fairweather, D.B., et al., "The Psychomotor and Cognitive Effects of Litoxetine in Young and Middle Aged Volunteers," Br. J. Clin. Pharmacol., 40(2):119-125 (1995).					
	AS4	Morteau, O., et al., "Influence of 5-HT ₃ Receptor Antagonists in Visceromotor and Nociceptive Responses to Rectal Distension Before and During Experimental Colitis In Rats," Fundam. Clin. Pharmacol., 8(6):553-562 (1994).					
	AT4	Goldberg, P.A., et al., "Modification of Visceral Sensitivity and Pain in Irritable Bowel Syndrome by 5-HT ₃ Antagonism (Ondansetron)," Digestion, 57(6):478-483 (1996).					
	AU4	LOTRONEX - Tablets, <i>Product Information</i> , GlaxoSmithKline, Research Triangle Park, NC, pp. 1-13 (2002).					
	AV4	"Irritable Bowel Syndrome at a Glance - Nosology, Epidemiology, and Pathophysiology (Monograph I), December 2002 [Retrieved on 2002-12-12]. Retrieved from the Internet VRL:http://fdhn.org/html/education/gi/ibs_nosology.htm> 					
	AW4	U.S. Provisional Application No. 60/364,531, filed 03-15-2002, entitled "Methods of Treating Visceral Pain Syndromes," by Rao <i>et al.</i> , priority document for WO 03/077897 A1 (Reference AQ2) and U.S. 2003/0203055 A1 (Reference AF4).					
	AX4	GB 0304648.9, filed 02-28-2003, entitled "New Therapeutic Use of 4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperzinyl) Thieno[2,3-D] Pyrimidine," priority document for WO 2004/004734 A1 (Reference AL2).					
	AY4	GB 0216027.3, filed July 10, 2002, entitled "New Therapeutic Use," priority document for WO 2004/004734 A1 (Reference AL2).					
	AZ4	Drossman, D.A., et al., "Irritable Bowel Syndrome: A Technical Review for Practice Guideline Development," Gastroenterology, 112: 2120-2137 (1997).					

EXAMINER Joy Chan	DATE CONSIDERED 7/16/57	
@PFDesktop\::ODMA/MHODMA/HBSPQS;iManage;450605;1		